Obesity Surgery

, Volume 26, Issue 7, pp 1525–1530 | Cite as

Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery

  • Anne Sophie Schneck
  • Rodolphe Anty
  • Albert Tran
  • Audrey Hastier
  • Imed Ben Amor
  • Jean Gugenheim
  • Antonio Iannelli
  • Thierry PicheEmail author
Original Contributions



Only a few recent reports have suggested a correlation between obesity and irritable bowel syndrome (IBS). We aimed to determine the prevalence and severity of IBS in a prospective cohort of obese patients undergoing bariatric surgery in Nice Hospital (France).


One hundred obese patients were included prospectively before bariatric surgery. A diagnosis of IBS and each subtype was performed according to Rome-III criteria using a Bristol scale for stool consistency. Patients provided information on IBS-related comorbidities, including chronic fatigue, migraine, lower back pain, gastroesophageal reflux disease (GERD), genitourinary problems, and dyspepsia. Patients completed questionnaires to assess the severity of IBS, GERD, psychological factors (anxiety, depression), fatigue, and quality of life.


Thirty patients fulfilled the Rome-III criteria for IBS. There was no difference in age, gender, or BMI between obese patients with or without IBS. Obese patients with IBS reported a significantly higher prevalence of GERD, migraines, lower back pain, genitourinary problems, chronic fatigue, and dyspepsia. Obese patients with IBS had significant higher scores of fatigue, anxiety, depression, and poorer quality of life. Obese patients that had both IBS and GERD had significantly higher IBS severity scores than those without GERD. In a logistic regression model including BMI, anxiety, depression, gender, and GERD score, only anxiety was significantly and independently associated with IBS.


Thirty percent of obese patients had IBS: its severity was not correlated with BMI. However, anxiety was independently associated with IBS, suggesting that psychological factors are key features of IBS, whatever the presence of obesity.


IBS Obesity 


Compliance with Ethical Standards

All patients in this study were included in a research project concerning both pathogenesis and treatment of IBS (Programme Hospitalier de Recherche Clinique, PHRC 2007–2008 of the CHU of Nice) with ethical approval from the “Comité de Protection des Personnes” on 6 November 2007 (No. 07.047).

Grant Support

Programme Hospitalier de Recherche Clinique (PHRC 2007–2008) of the CHU of Nice

Conflict of Interest

All authors have no conflicts of interest relevant to the manuscript.


  1. 1.
    Hruby A, Hu FB. The Epidemiology of obesity: a big picture. Pharmacoeconomics. 2014.Google Scholar
  2. 2.
    David K, Kowdley KV, Unalp A, et al. Schwimmer JB; NASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(6):1904–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Delgado-Aros S, Locke GR, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population based study. Am J Gastroenterol. 2004;99(9):1801–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Talley NJ, Quan C, Jones MP, et al. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil. 2004;16(4):413–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010;22(1):102–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Cremonini F, Camilleri M, Clark MM, et al. Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. Int J Obes. 2009;33(3):342–53.CrossRefGoogle Scholar
  7. 7.
    Clements RH, Gonzalez QH, Foster A, et al. Mc- Dowell J, Bondora A, et al. Gastrointestinal symptoms are more intense in morbidly obese patients and are improved with laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2003;13(4):610–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Roberson EN, Gould JC, Wald A. Urinary and fecal incontinence after bariatric surgery. Dig Dis Sci. 2010;55(9):2606–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Fysekidis M, Bouchoucha M, Bihan H, et al. Prevalence and co-occurrence of upper and lower functional gastrointestinal symptoms in patients eligible for bariatric surgery. Obes Surg. 2012;22(3):403–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Carter D, Beer-Gabel M, Tzur D, et al. Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults. Clin Gastroenterol. 2015;49(4):300–5.CrossRefGoogle Scholar
  11. 11.
    Iannelli A, Anty R, Piche T, et al. Impact of laparoscopic Roux-en-Y gastric bypass on metabolic syndrome, inflammation, and insulin resistance in super versus morbidly obese women. Obes Surg. 2009;19(5):577–82.CrossRefPubMedGoogle Scholar
  12. 12.
    Anty R, Dahman M, Iannelli A, et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg. 2008;18(6):709–14.CrossRefPubMedGoogle Scholar
  13. 13.
    NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956–61.Google Scholar
  14. 14.
    Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402.CrossRefPubMedGoogle Scholar
  16. 16.
    Piche T, Ducrotté P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(6):626–e174.CrossRefPubMedGoogle Scholar
  17. 17.
    Fisk JD, Pontrefact A, Ritvo PF, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Can J Neurol Sci. 1994;18 Suppl 1:S79–83.Google Scholar
  18. 18.
    Huet PM, Deslauriers J, Tran A, et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol. 2000;95(3):760–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57(4):468–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Sacher-Huvelin S, Gournay J, Amouretti M, et al. Bruley Des Varannes S, Galmiche JP. Acid-sensitive esophagus: natural history and effect on the quality of life. Comparison with gastroesophageal reflux. Gastroenterol Clin Biol. 2000;24(10):911–6.PubMedGoogle Scholar
  22. 22.
    Dapoigny M, Bellanger J, Bonaz B. Bruley des Varannes S, Bueno L, Coffin B, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol. 2004;16(10):995–1001.CrossRefPubMedGoogle Scholar
  23. 23.
    Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Marshall JK, Thabane M, Garg AX, et al. Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605–11.CrossRefPubMedGoogle Scholar
  25. 25.
    Scarpellini E, Lupo M, Iegri C, et al. Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis. Rev Recent Clin Trials. 2014;9(3):141–7.PubMedGoogle Scholar
  26. 26.
    Ma YY, Li L, Yu CH, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Anne Sophie Schneck
    • 1
    • 4
  • Rodolphe Anty
    • 2
    • 4
  • Albert Tran
    • 2
    • 4
  • Audrey Hastier
    • 2
  • Imed Ben Amor
    • 1
  • Jean Gugenheim
    • 1
    • 4
  • Antonio Iannelli
    • 1
    • 4
  • Thierry Piche
    • 2
    • 3
    Email author
  1. 1.Service de Chirurgie Digestive et Transplantation Hépatique, Hôpital Archet 2, Pôle Digestif, CHU NiceUniversité de Nice Sophia-AntipolisNiceFrance
  2. 2.Service d’Hépato-Gastroentérologie et de Cancérologie Digestive, Hôpital Archet 2, Pôle Digestif, CHU de NiceUniversité de Nice Sophia-AntipolisNiceFrance
  3. 3.Service d’Immunologie, Pôle Biologie, EA 6302 Tolérance ImmunitaireHôpital Archet 1 Université de Nice Sophia-AntipolisNiceFrance
  4. 4.INSERM, U1065, Team 8 “Hepatic complications in obesity”, C3MNiceFrance

Personalised recommendations